期刊
ANNALS OF MEDICINE
卷 37, 期 6, 页码 404-412出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/07853890500284937
关键词
antidepressants; adolescents; children; depression; suicidality
资金
- NIMH NIH HHS [K01 MH69948, R01 MH56612, P30 MH66371] Funding Source: Medline
- NATIONAL INSTITUTE OF MENTAL HEALTH [K01MH069948, R01MH056612, P30MH066371] Funding Source: NIH RePORTER
The U.S. Food and Drug Administration (FDA) has mandated that all antidepressants carry a 'black box' warning label indicating that antidepressants increase the risk of suicidality in youth taking these medications. In the U.K., the Medicine and Healthcare Products Regulatory Agency (MHRA) has determined that the balance of risks and benefits favors only the use of fluoxetine in the treatment of depressive illness in children and adolescents. This article reviews the FDA's analysis linking antidepressant medication use and pediatric suicidality in major depressive disorder, discusses the efficacy of antidepressants in treating depression in children and adolescents, and offers suggestions to aid clinicians, patients, and families in making clinical decisions based on an accurate assessment of the benefits and risks of medication and psychosocial treatments for pediatric depression.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据